ImmuCell Corporation (NASDAQ:ICCC - Get Free Report)'s stock price crossed above its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $5.43 and traded as high as $6.76. ImmuCell shares last traded at $6.39, with a volume of 3,325 shares changing hands.
ImmuCell Stock Up 5.1%
The firm has a market cap of $60.70 million, a price-to-earnings ratio of -95.91 and a beta of 0.32. The stock has a 50-day moving average of $6.10 and a 200-day moving average of $5.48. The company has a current ratio of 4.12, a quick ratio of 2.21 and a debt-to-equity ratio of 0.30.
ImmuCell (NASDAQ:ICCC - Get Free Report) last announced its quarterly earnings results on Wednesday, May 14th. The biotechnology company reported $0.16 earnings per share (EPS) for the quarter. The company had revenue of $8.07 million during the quarter. ImmuCell had a negative net margin of 1.00% and a negative return on equity of 1.02%.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Mesirow Financial Investment Management Inc. increased its stake in shares of ImmuCell by 100.0% in the fourth quarter. Mesirow Financial Investment Management Inc. now owns 24,356 shares of the biotechnology company's stock valued at $125,000 after purchasing an additional 12,178 shares during the period. Citadel Advisors LLC bought a new position in ImmuCell in the 4th quarter worth approximately $149,000. Northern Trust Corp grew its holdings in ImmuCell by 51.0% in the 4th quarter. Northern Trust Corp now owns 44,374 shares of the biotechnology company's stock worth $229,000 after buying an additional 14,982 shares in the last quarter. Geode Capital Management LLC increased its position in ImmuCell by 13.9% in the 4th quarter. Geode Capital Management LLC now owns 64,538 shares of the biotechnology company's stock valued at $332,000 after acquiring an additional 7,878 shares during the period. Finally, Dauntless Investment Group LLC bought a new stake in ImmuCell during the 4th quarter valued at $676,000. 13.47% of the stock is owned by institutional investors and hedge funds.
About ImmuCell
(
Get Free Report)
ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E.
See Also
Before you consider ImmuCell, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ImmuCell wasn't on the list.
While ImmuCell currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
